Transcode Therapeutics Files Amendment to S-1 Registration Statement

TL;DR

<b>Transcode Therapeutics, Inc. has filed an S-1/A amendment, indicating progress towards a public offering of securities.</b>

AI Summary

Transcode Therapeutics, Inc. (RNAZ) filed a Amended IPO Registration (S-1/A) with the SEC on January 18, 2024. Transcode Therapeutics, Inc. filed an amendment (S-1/A) to its registration statement on January 18, 2024. The filing is related to the Securities Act of 1933, with registration number 333-276467. The company's principal executive offices are located at 6 Liberty Square, #2382, Boston, MA 02109. Thomas A. Fitzgerald is listed as the Interim Chief Executive Officer. The filing indicates the proposed sale of securities will commence as soon as practicable after the effective date.

Why It Matters

For investors and stakeholders tracking Transcode Therapeutics, Inc., this filing contains several important signals. This S-1/A filing is a procedural step for Transcode Therapeutics to potentially offer its securities to the public, which could provide capital for its operations and growth. The amendment suggests the company is actively working towards becoming a publicly traded entity, which could impact its valuation and investor base.

Risk Assessment

Risk Level: low — Transcode Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating a procedural step rather than a significant event with immediate financial implications.

Analyst Insight

Monitor for the effectiveness of the registration statement and subsequent public offering details to assess potential investment opportunities.

Key Numbers

• 2024-01-18 — Filing Date (Date of S-1/A filing)
• 333-276467 — Registration Number (Securities Act of 1933 registration)
• 6 Liberty Square, #2382 — Principal Office Address (Boston, MA 02109)
• 857-301-6857 — Business Phone (Contact number for the company)

Key Players & Entities

• Transcode Therapeutics, Inc. (company) — Registrant
• Thomas A. Fitzgerald (person) — Interim Chief Executive Officer
• Goodwin Procter LLP (company) — Legal Counsel
• Michael Bison (person) — Legal Counsel
• Finnbarr Murphy (person) — Legal Counsel
• Ellenoff Grossman & Schole LLP (company) — Legal Counsel
• John J. Hart, Esq. (person) — Legal Counsel
• 333-276467 (regulator) — Registration Number

Forward-Looking Statements

• Transcode Therapeutics will proceed with a public offering of securities. (Transcode Therapeutics, Inc.) — high confidence, target: Q1 2024
• The public offering will be conducted on a continuous basis. (Transcode Therapeutics, Inc.) — high confidence, target: Ongoing

FAQ

Industry Context

Transcode Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track future SEC filings from Transcode Therapeutics for updates on the offering's progress.
3. Research the company's business model and therapeutic pipeline to understand its market potential.

Key Dates

• 2024-01-18: Filing of S-1/A Amendment — Indicates progress in the registration process for a public securities offering.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing regulatory processes rather than a comparison to a prior period's financial performance.

Key Financial Figures

• $2 — nying common stock purchase warrants is $2.16, which was the closing price of our
• $ — ill have an exercise price per share of $, will be exercisable upon issuance and
• $0 — d to the public in this offering, minus $0.01, and the exercise price of each pre-
• $0.01 — rice of each pre-funded warrant will be $0.01 per share. For each pre-funded warrant
• $2.16 — Capital Market on January 17, 2024, was $2.16 per share. The final public offering pr
• $2,500,000 — intain stockholders' equity of at least $2,500,000. The Nasdaq Hearings Panel has informed
• $50,000 — accountable expenses in an amount up to $50,000, legal fees and other out-of-pocket exp
• $100,000 — -pocket expenses in the amount of up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $136.9 billion — r treatment market is expected to reach $136.9 billion by 2032 (July 6, 2023 /PRNewswire/ —All

Filing Documents

• tm2333928-7_s1a.htm (S-1/A) — 3505KB
• tm2333928d8_ex4-3.htm (EX-4.3) — 111KB
• tm2333928d8_ex5-1.htm (EX-5.1) — 13KB
• tm2333928d8_ex10-14.htm (EX-10.14) — 210KB
• tm2333928d8_ex23-1.htm (EX-23.1) — 3KB
• tm2331229d6_ex-filingfees.htm (EX-FILING FEES) — 22KB
• lg_transcodetheraptm-4c.jpg (GRAPHIC) — 10KB
• fc_therapeutics-4clr.jpg (GRAPHIC) — 43KB
• fc_currentpipeline-4clr.jpg (GRAPHIC) — 35KB
• fc_therapeutic-4clr.jpg (GRAPHIC) — 60KB
• fc_figure1-4clr.jpg (GRAPHIC) — 93KB
• fc_figure2-4clr.jpg (GRAPHIC) — 46KB
• fc_figure3-4clr.jpg (GRAPHIC) — 211KB
• fc_figure4-4clr.jpg (GRAPHIC) — 120KB
• fc_figure5-4clr.jpg (GRAPHIC) — 111KB
• fc_figure6-4clr.jpg (GRAPHIC) — 67KB
• fc_figure7-4clr.jpg (GRAPHIC) — 50KB
• fc_figure8-4clr.jpg (GRAPHIC) — 93KB
• lc_figure9-4clr.jpg (GRAPHIC) — 69KB
• lc_figure10-4clr.jpg (GRAPHIC) — 59KB
• fc_figure11-4clr.jpg (GRAPHIC) — 76KB
• lc_figure12-4clr.jpg (GRAPHIC) — 53KB
• fc_figure13-4clr.jpg (GRAPHIC) — 65KB
• fc_figure14-4clr.jpg (GRAPHIC) — 100KB
• lc_figure15-4clr.jpg (GRAPHIC) — 30KB
• 0001104659-24-004721.txt (&nbsp;) — 5783KB

Risk Factors

Risk Factors 24 Cautionary Note Regarding Forward-Looking Statements 90 Industry and Other Data 92

Use of Proceeds

Use of Proceeds 94 Dividend Policy 95 Capitalization 96

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 100

Business

Business 122 Management 172

Executive Compensation

Executive Compensation 180 Certain Relationships and Related Party Transactions 186 Principal Stockholders 187

Description of Capital Stock

Description of Capital Stock 189 Material U.S. Federal Income Tax Considerations 199 Plan of Distribution 206 Legal Matters 209 Experts 209 Index to Financial Statements F-1 Neither we nor the placement agent have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on our behalf or to which we have referred you. We and the placement agent take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We and the placement agent are offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and future prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. We and the placement agent are offering to sell, and seeking offers to buy, our shares of common stock and pre-funded warrants only in jurisdictions where offers and sales are permitted. Neither we nor the placement agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United

View Full Filing

View this S-1/A filing on SEC EDGAR